23.30
+0.74(+3.28%)
Currency In USD
| Previous Close | 22.56 |
| Open | 22.62 |
| Day High | 23.46 |
| Day Low | 22.57 |
| 52-Week High | 30.48 |
| 52-Week Low | 16.1 |
| Volume | 491,558 |
| Average Volume | 2.89M |
| Market Cap | 2.95B |
| PE | 64.72 |
| EPS | 0.36 |
| Moving Average 50 Days | 23.3 |
| Moving Average 200 Days | 22.07 |
| Change | 0.74 |
If you invested $1000 in Apellis Pharmaceuticals, Inc. (APLS) since IPO date, it would be worth $1,660.73 as of February 06, 2026 at a share price of $23.3. Whereas If you bought $1000 worth of Apellis Pharmaceuticals, Inc. (APLS) shares 5 years ago, it would be worth $474.35 as of February 06, 2026 at a share price of $23.3.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 12, 2026 12:00 PM GMT
Full-year 2025 preliminary1 U.S. net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) total injection demand grew 17% year-over-year; regulatory submission for prefilled syringe planned in 1H 2026Strong EMPAVELI® (pegcetacoplan) lau
Apellis Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 05, 2026 12:00 PM GMT
WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 11:15 a.m. PT. The liv
The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN
GlobeNewswire Inc.
Dec 03, 2025 10:05 PM GMT
Robust and clinically meaningful benefits across all three key markers of disease – 68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of C3 depositsConsistent results across adolescent and adult patients with C